<think>
Let me analyze the search results to create a comprehensive forecast for Eli Lilly and Company (LLY) for Q2 2025. 

Looking at the provided search results, I need to extract key financial information:

From search result [1]: 247wallst.com provides these forecasts:
- 2025: Revenue $52.80 billion, Net Income $17.29 billion, EPS $19.11
- 2026: Revenue $62.50 billion, Net Income $22.49 billion, EPS $25.03

From search result [2]: Lilly's Q4 2024 results and 2025 guidance:
- Q4 2024 revenue: $13.53 billion (45% increase)
- 2025 guidance: revenue $58.0 billion to $61.0 billion, EPS $22.05 to $23.55

From search result [4]: For Q2 2025 (ending June 2025), consensus EPS forecast is 5.61

From search result [6]: Revenue expected to reach 15.81B USD in next quarter

Let me structure this as an equity research report with original analysis. I need to be careful not to copy other analysts' work directly but use the data points to create my own forecasts.

Key factors affecting the forecast:
1. GLP-1 drugs (Mounjaro/Zepbound) driving significant growth
2. Patent expirations coming for some drugs
3. New drug approvals (Kisunla for Alzheimer's, orforglipron potential)
4. Manufacturing expansion with $27B investment
5. Competitive landscape in obesity/diabetes market

For Q2 2025 specifically, I need to forecast:
- Revenue
- EBITDA
- Operating Income
- Net Income
- Free Cash Flow
- EPS

Let me analyze the quarterly progression and trends to make reasonable Q2 2025 estimates:


I anticipate Q2 2025 will show continued strong performance, with revenue likely hitting around $15.5 billion. The midpoint of annual guidance suggests quarterly revenues of approximately $14.9 billion, but seasonal trends and the momentum of Zepbound/Mounjaro indicate potential for slight overperformance. The consensus EPS of $5.61 appears conservative given the company's growth trajectory in obesity and diabetes treatments.

Key drivers will include:
- Continued expansion of GLP-1 drug market share
- Strong performance of Zepbound in obesity treatment
- Potential new market opportunities in Alzheimer's treatment
- Ongoing manufacturing investments supporting growth

The forecast suggests Eli Lilly is positioned for robust financial performance in Q2 2025, with potential upside to current consensus estimates.
</think>

# Eli Lilly and Company (LLY) Financial Forecast for Q2 2025

This comprehensive financial forecast for Eli Lilly and Company presents detailed projections for the second quarter of 2025, based on extensive analysis of the company's recent performance, strategic initiatives, and market dynamics. The forecast indicates continued robust growth driven by the exceptional performance of the company's GLP-1 therapies, Mounjaro and Zepbound, which have fundamentally transformed Eli Lilly's financial trajectory and positioned the company as a dominant force in the rapidly expanding obesity and diabetes treatment markets. The analysis incorporates the company's recent manufacturing expansion announcements, pipeline developments, competitive positioning, and the broader pharmaceutical market trends that will influence performance through the forecast period.

## Market Position and Strategic Context

Eli Lilly has emerged as the pharmaceutical industry's growth leader, largely propelled by its groundbreaking GLP-1 receptor agonists that have captured significant market share in both diabetes and obesity treatment segments[1][2]. The company's strategic positioning reflects a fundamental shift in the pharmaceutical landscape, where Eli Lilly has transitioned from a traditional diabetes-focused company to a comprehensive metabolic health powerhouse with global reach and market leadership aspirations[13].

The company's market capitalization has experienced extraordinary growth, reaching $852.5 billion by the end of 2024, representing more than a doubling from approximately $325.6 billion in 2022[26]. This remarkable valuation expansion reflects investor confidence in the company's long-term growth prospects, driven primarily by the success of tirzepatide-based therapies and the anticipated approval of next-generation treatments, including the oral GLP-1 candidate orforglipron[8][21].

Eli Lilly's competitive advantages extend beyond its current product portfolio to encompass manufacturing capabilities, distribution networks, and research and development infrastructure that create substantial barriers to entry for competitors[17]. The company's recent announcement of a $27 billion investment in United States manufacturing facilities demonstrates its commitment to scaling production capacity to meet growing global demand, while also securing supply chain resilience and operational efficiency[12].

The strategic context for the Q2 2025 forecast also incorporates the company's expanding therapeutic focus, which now includes significant investments in Alzheimer's disease treatment with Kisunla receiving FDA approval with an improved dosing regimen[28]. This diversification strategy reduces dependence on any single therapeutic area while capitalizing on the company's expertise in complex disease mechanisms and drug development capabilities.

## Revenue Growth Dynamics and Forecasting Methodology

The revenue forecast for Q2 2025 builds upon several key growth drivers that have established sustainable momentum throughout 2024 and into early 2025. The most significant contributor to revenue growth continues to be the GLP-1 therapy portfolio, with Mounjaro generating $3.1 billion in Q2 2024 compared to $979.7 million in the same period of the previous year[15]. This exceptional growth trajectory, combined with Zepbound's rapid market penetration following its November 2023 launch, creates a foundation for continued robust revenue expansion[15].

The company's full-year 2025 revenue guidance of $58.0 billion to $61.0 billion provides a framework for quarterly projections, suggesting an average quarterly revenue of approximately $14.75 billion to $15.25 billion[2]. However, seasonal patterns and product launch dynamics indicate that Q2 typically represents a period of accelerated growth, particularly for metabolic therapies as healthcare providers and patients focus on weight management initiatives following the first quarter[2].

International revenue expansion represents another critical component of the revenue forecast, with the company's global market penetration strategies showing positive results across key international markets[9]. The introduction of KwikPen delivery systems and expanded access programs in international markets has contributed to volume growth that complements price optimization strategies in mature markets[15].

The revenue forecasting methodology also accounts for pricing dynamics within the GLP-1 market, where Eli Lilly has demonstrated pricing power despite increasing competitive pressure from Novo Nordisk and emerging competitors[14]. The company's ability to maintain premium pricing reflects the clinical superiority and convenience factors associated with its therapies, particularly as insurance coverage expands and accessibility improves[14].

Based on these factors and the observed quarterly progression patterns, the Q2 2025 revenue forecast projects total quarterly revenue of $15,650,000,000, representing a sequential increase from Q1 2025 estimates and positioning the company to achieve the upper end of its full-year guidance range[2][15].

## EBITDA and Operating Performance Analysis

The EBITDA forecast for Q2 2025 reflects the company's exceptional operational leverage, driven by the high-margin characteristics of its GLP-1 therapies and the continued optimization of its manufacturing and distribution operations[2]. The company's gross margin expansion to 83.2% in Q4 2024, representing an increase of 0.9 percentage points year-over-year, demonstrates the favorable product mix effect as higher-margin new products constitute an increasing proportion of total sales[2].

Operating efficiency improvements stem from several sources, including economies of scale achieved through increased production volumes, manufacturing process optimizations, and the strategic deployment of advanced manufacturing technologies across the company's expanding production network[12]. The $27 billion manufacturing investment program is expected to yield operational efficiencies that will contribute to EBITDA margin expansion over the forecast period[12].

The EBITDA calculation also incorporates increased research and development expenses associated with the company's robust pipeline development activities, including late-stage trials for orforglipron and continued investment in Alzheimer's disease research[8][21]. However, these investments are offset by the exceptional cash generation from existing products and the operational leverage achieved through revenue growth[9].

Sales and marketing expenses are expected to increase in absolute terms but decrease as a percentage of revenue, reflecting the established market position of Mounjaro and Zepbound and the reduced need for intensive promotional spending as these products achieve market leadership[1]. The company's direct-to-consumer marketing initiatives and healthcare provider education programs represent strategic investments that support long-term market share expansion while maintaining cost efficiency[9].

The Q2 2025 EBITDA forecast of $10,750,000,000 represents an EBITDA margin of approximately 68.7%, reflecting the continuation of the company's exceptional profitability profile while accounting for strategic investments in capacity expansion and pipeline development[2][12].

## Operating Income Projections and Profitability Analysis

Operating income projections for Q2 2025 incorporate the impact of increased depreciation expenses associated with the company's substantial capital investment program, while maintaining the strong operational leverage that characterizes Eli Lilly's current financial profile[12]. The operating income forecast reflects the company's ability to generate exceptional returns on invested capital through its market-leading products and operational excellence initiatives[26].

The depreciation impact from new manufacturing facilities and production equipment represents a temporary headwind to operating income growth rates, but these investments are essential for supporting long-term revenue growth and market share expansion[12]. The company's strategic approach to capital allocation prioritizes investments that enhance competitive positioning and create sustainable barriers to entry in key therapeutic markets[12].

Operating leverage continues to benefit from the fixed-cost nature of many research and development activities, where successful product launches generate substantial incremental operating income without proportional increases in development expenses[9]. The company's established pipeline of late-stage development candidates provides visibility into future operating income growth beyond the immediate forecast period[8][21].

Administrative and corporate expenses are expected to increase modestly in absolute terms but decline as a percentage of revenue, reflecting the scalability of the company's corporate infrastructure and the efficiency gains achieved through digital transformation initiatives[9]. The company's investment in artificial intelligence and data analytics capabilities supports operational efficiency improvements across multiple functional areas[27].

The Q2 2025 operating income forecast of $8,200,000,000 represents an operating margin of approximately 52.4%, maintaining the company's position among the most profitable pharmaceutical companies while supporting strategic investments in growth initiatives[2][12].

## Net Income and Earnings Per Share Forecasting

The net income forecast for Q2 2025 incorporates several key factors that influence the company's after-tax profitability, including effective tax rate optimization, interest expense management, and the impact of foreign exchange fluctuations on international operations[2]. The company's effective tax rate of 12.5% in Q4 2024 provides a baseline for projecting tax expenses, though quarterly variations may occur based on the geographic mix of earnings and discrete tax items[2].

Interest expense is expected to remain manageable despite the company's substantial capital investment program, reflecting the company's strong credit profile and access to favorable financing terms[20]. The debt-to-EBITDA ratio is projected to remain below 1.0 times by 2025, providing financial flexibility for continued strategic investments while maintaining conservative leverage metrics[20].

Foreign exchange impacts on net income are expected to be modest in Q2 2025, though the company's expanding international operations create both opportunities and risks associated with currency fluctuations[9]. The company's natural hedging through international manufacturing and supply chain operations helps mitigate foreign exchange volatility[9].

Share count for earnings per share calculations reflects the company's historical approach to capital allocation, which has generally favored dividend payments and strategic investments over aggressive share repurchase programs[22]. The weighted average share count for Q2 2025 is projected at approximately 900 million shares, consistent with recent quarterly averages[2].

The Q2 2025 net income forecast of $5,040,000,000 translates to earnings per share of $5.60, which aligns with analyst consensus expectations while reflecting the company's continued earnings growth trajectory[4][6].

## Free Cash Flow Generation and Capital Allocation

Free cash flow projections for Q2 2025 reflect the company's exceptional cash generation capabilities, tempered by the substantial capital expenditures associated with manufacturing capacity expansion and infrastructure development[12]. The company's free cash flow generation has historically been robust, supported by the favorable working capital characteristics of pharmaceutical operations and the high cash conversion rates of its products[20].

Capital expenditures in Q2 2025 are expected to be elevated due to the ongoing $27 billion manufacturing investment program, with quarterly capital spending projected at approximately $2.5 billion as facility construction and equipment installation activities reach peak levels[12]. These investments represent strategic necessities for supporting long-term growth rather than discretionary spending, as manufacturing capacity constraints could limit revenue growth potential[12].

Working capital dynamics are expected to be favorable in Q2 2025, with inventory levels optimized to support growing demand while minimizing carrying costs[2]. The company's sophisticated demand forecasting and supply chain management systems enable efficient working capital utilization while ensuring product availability across global markets[9].

The free cash flow calculation also incorporates the timing of research and development expenditures, which may exhibit some quarterly variability based on clinical trial milestones and regulatory submission activities[8][21]. However, the company's established development processes and pipeline management capabilities provide reasonable predictability for cash flow forecasting purposes[9].

The Q2 2025 free cash flow forecast of $2,540,000,000 represents free cash flow yield of approximately 0.4% based on current market capitalization, reflecting the company's investment phase while maintaining substantial cash generation capabilities[12][26].

## Risk Factors and Sensitivity Analysis

The financial forecast for Q2 2025 incorporates several key risk factors that could influence actual results, including competitive dynamics in the GLP-1 market, regulatory developments affecting pricing and market access, and potential supply chain disruptions[10][17]. The most significant risk factor relates to competitive pressure from existing players such as Novo Nordisk and emerging competitors developing next-generation obesity and diabetes treatments[10][14].

Regulatory risks include potential changes to Medicare price negotiation programs, which could affect pricing power for key products, though the company's newest products are generally protected from immediate pricing pressure[17]. The FDA approval timeline for orforglipron represents both an opportunity and a risk, as delays could affect growth expectations while successful approval could accelerate revenue growth[8][21].

Manufacturing and supply chain risks associated with the rapid scaling of GLP-1 production capacity could potentially constrain revenue growth if demand exceeds supply capabilities[12]. However, the company's substantial manufacturing investments are designed to mitigate these risks and provide adequate capacity for projected demand growth[12].

Patent expiration risks for older products including Jardiance and Trulicity create headwinds to revenue growth, though the impact is expected to be more than offset by new product launches and market share gains in growth categories[19]. The company's patent strategy and product lifecycle management capabilities provide some protection against generic competition[19].

Market access and insurance coverage changes represent ongoing risks that could affect demand for GLP-1 therapies, particularly in the obesity indication where coverage policies continue to evolve[14]. However, the company's health economics research and market access initiatives are designed to demonstrate value and support favorable coverage decisions[14].

## Conclusion and Investment Implications

The comprehensive financial forecast for Eli Lilly's Q2 2025 performance indicates continued exceptional growth across key financial metrics, driven by the sustained success of the company's GLP-1 therapy portfolio and strategic investments in manufacturing capacity and pipeline development. The projected financial results position Eli Lilly to maintain its leadership in the rapidly growing metabolic health market while building capabilities for long-term competitive advantage.

The forecast reflects a company in a unique position within the pharmaceutical industry, benefiting from multiple favorable trends including increasing obesity prevalence, expanding treatment paradigms, and growing recognition of the broader health benefits associated with GLP-1 therapies[25]. The company's strategic investments in manufacturing, research and development, and market access initiatives demonstrate management's commitment to capitalizing on these opportunities while building sustainable competitive advantages[12].

Risk factors remain manageable within the context of the company's strong financial position and market leadership, though investors should monitor competitive developments, regulatory changes, and manufacturing execution as key variables that could influence future performance[10][17]. The company's diversification into Alzheimer's disease treatment and continued pipeline development provide additional avenues for growth beyond the core metabolic health franchise[24][28].

The financial projections presented in this analysis reflect a conservative approach that accounts for known risk factors while recognizing the exceptional growth trajectory that characterizes Eli Lilly's current business performance. The company's financial strength, market position, and strategic execution capabilities support confidence in achieving the forecasted results while positioning for continued growth beyond the immediate forecast period.

## Financial Forecast Summary

| Company | Year | Quarter | Revenue | EBITDA | Operating Income | Net Income | Free Cash Flow | EPS |
|---------|------|---------|---------|---------|------------------|------------|----------------|-----|
| Eli Lilly | 2025 | 2 | 15650000000 | 10750000000 | 8200000000 | 5040000000 | 2540000000 | 5.60 |